AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Mitochondrial tRNA methylthiotransferase CDK5RAP1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96SZ6

UPID:

CK5P1_HUMAN

Alternative names:

CDK5 activator-binding protein C42; CDK5 regulatory subunit-associated protein 1; mt-tRNA-2-methylthio-N6-dimethylallyladenosine synthase; mt-tRNA-N6-(dimethylallyl)adenosine(37) methylthiotransferase

Alternative UPACC:

Q96SZ6; A8K7R0; Q5QP46; Q5QP47; Q5QP48; Q675N4; Q675N5; Q9BVG6; Q9BWZ5; Q9H859; Q9NZZ9; Q9Y3F0

Background:

Mitochondrial tRNA methylthiotransferase CDK5RAP1, also known as CDK5 activator-binding protein C42, plays a pivotal role in mitochondrial protein synthesis. It catalyzes the conversion of N6-(dimethylallyl)adenosine to 2-methylthio-N6-(dimethylallyl)adenosine at position 37 of mitochondrial DNA-encoded tRNAs. This enzymatic activity is crucial for accurate protein translation and respiratory chain efficiency, highlighting its importance in mitochondrial function.

Therapeutic significance:

Understanding the role of Mitochondrial tRNA methylthiotransferase CDK5RAP1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.